Small molecule · developed by Supergen
Mitomycin is an antineoplastic antibiotic that alkylates DNA, producing interstrand cross-links that inhibit DNA synthesis; at high concentrations it also suppresses RNA and protein synthesis. It is studied in urothelial carcinoma of the upper urinary tract and bladder, delivered locally via pyelocalyceal solution, intravesical administration, or a sustained-release hydrogel formulation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 9, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05243550 | Phase 3 | Bladder Cancer | Active not recruiting | URGN |
| NCT02793128 | Phase 3 | Carcinoma, Transitional Cell | Completed | URGN |
| NCT02307487 | Phase 2 | Bladder Cancer | Completed | URGN |
| NCT00318643 | Phase 1/2 | Bladder Cancer | Completed | HALO |
| NCT05874921 | N/A | Urothelial Carcinoma | Recruiting | URGN |
| NCT02701023 | N/A | Urothelial Carcinoma Ureteral Location | No longer available | URGN |
| NCT05494411 | N/A | Urothelial Cancer of Renal Pelvis | Available | URGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Urothelial CarcinomaUrothelial Carcinoma BladderBladder CancerCarcinoma, Transitional CellNeoplasmsTransitional Cell Carcinoma of Renal PelvisUrinary Bladder DiseasesUrologic DiseasesUrothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma RecurrentUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial Carcinoma Ureteral Location
Updated Nov 8, 2026.